Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering ATLANTA

Therapeutics, Inc. Announces Pricing of its Initial Public Offering

ATLANTA, December 22, 2020- Inhibikase Therapeutics,

Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders

that arise inside and outside of the brain, announced today the pricing of its initial public offering of 1,800,000 shares of common

stock at a public offering price of $10.00 per share, for gross proceeds of $18 million, before deducting underwriting discounts

and commissions and other offering expenses payable by Inhibikase. All of the shares are being offered by Inhibikase. In addition,

Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of common stock at the initial

public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Capital

Market on December 23, 2020 under the ticker symbol "IKT." The offering is expected to close on December 28, 2020, subject

to the satisfaction of customary closing conditions.

ThinkEquity, a division of Fordham Financial

Management, Inc., is acting as sole book-running manager for the offering.

A registration statement relating to the

securities being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on December 22, 2020.

This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained,

when available, from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor,

New York, New York 10004, by telephone at (877) 436-3673, or by email at prospectus@think-equity.com. These documents may

also be obtained free of charge, when they are available, by visiting the SEC's website at www.sec.gov.

This press release shall not constitute

an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any

state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under

the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will

be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Inhibikase (www.inhibikase.com)

Inhibikase is a clinical-stage pharmaceutical company developing

therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered

in Atlanta, Georgia with additional offices in Boston, Massachusetts.

press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act

of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should,"

"anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended

to identify forward-looking statements. These forward-looking statements,

including statements regarding the closing of the initial public offering and the proceeds of the initial public offering, are

based on Inhibikase's current expectations and assumptions. Such statements are subject

to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated

by the forward-looking statements. Important factors that could cause

actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with

the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk

Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes

no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments

or otherwise, except as may be required by any applicable securities laws.

Milton H. Werner, PhD

President & CEO, Inhibikase

M2Friend Biocommunications